The Valley Desk

ArticleCancerPublished

Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name GSK, University of Pennsylvania. Affiliation source

Publication record

Type
Article
Venue
Cancer
Published
Subject terms
Humans; Multiple Myeloma; Treatment Outcome; Quality of Life; Antibodies, Monoclonal, Humanized; Monoclonal antibody; Multiple myeloma; Clinical Activity; Antibody-drug Conjugate; B-cell Maturation Antigen
PubMed ID
37622738
PubMed Central ID
PMC11055177
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal